Plus Therapeutics (BIO 2022) - Jun 4, 2022 - Pres time: Jun 15, 2022; 10:30 AM - 10:45 AM; Location: Theater 4; "Our proprietary radiotherapeutic platform uniquely uses nanoliposomes to encapsulate and deliver the radioisotope, Rhenium, into or near a tumor via a single, direct infusion. The lead radiotherapeutic in our pipeline, Rhenium-186 NanoLiposome (186RNL), is being evaluated in U.S. multi-center clinical trials for the treatment of recurrent glioblastoma and leptomeningeal metastases."
Brain Cancer • Glioblastoma • Oncology • Solid Tumor
|